Skip to main content
Vivo Bio tech Ltd. logo

Vivo Bio tech Ltd. — Investor Relations & Filings

Ticker · 511509 ISIN · INE380K01017 LEI · 98450079E4M2CR80D882 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 440 across all filing types
Latest filing 2023-12-30 Regulatory Filings
Country IN India
Listing BSE.NS 511509

About Vivo Bio tech Ltd.

http://www.vivobio.com/

Vivo Bio Tech Ltd. is a preclinical Contract Research Organization (CRO) providing comprehensive drug discovery and development services. The company specializes in conducting in vivo preclinical studies, including toxicology, pharmacology, and pharmacokinetic evaluations. It operates advanced facilities for the breeding and distribution of Specific Pathogen Free (SPF) laboratory animal models, maintained through strategic partnerships with global leaders like Taconic Biosciences. Vivo Bio Tech offers regulatory-compliant services such as safety assessment, efficacy testing, and specialized research models to support pharmaceutical and biotechnology sectors. Its operations are characterized by adherence to Good Laboratory Practice (GLP) standards and AAALAC accreditation, ensuring high-quality data for global regulatory submissions.

Recent filings

Filing Released Lang Actions
Please find enclosed the trading window closure notice in respect of qtr ending 31st December, 2023.
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchange about the closure of the trading window for insiders due to upcoming financial results. It references SEBI regulations and mentions the period of closure related to the announcement of unaudited financial results for the third quarter and nine months ended December 31, 2023. The document does not contain any financial data or detailed report but is an announcement related to trading restrictions ahead of financial disclosures. The length is only 1487 characters, indicating it is a brief notice rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance notice rather than a financial report or earnings release.
2023-12-30 English
Vivo Bio Tech Limited has infirmed the exchange about the resignation of Ms. Jyotika Aasat as the Company Secretary and Compliance Officer of the Company w.e.f. January 02, 2024
Regulatory Filings
2023-12-23 English
Vivo Bio Tech Limited has submitted with the exchange the copies of Newspaper Publication for Un-Audited Financial Results of the Company for the secodn quarter and half-year ended September 30, 2023
Regulatory Filings
2023-11-16 English
Vivo Bio Tech Limited has submitted with the exchange the Un-Audited Financial Results of the Company for the second quarter and half year ended September 30, 2023
Regulatory Filings
2023-11-14 English
Vivo Bio Tech Limited has informed the exchange about the Outcome of Board Meeting for Approval Of Un-Audited Standalone & Consolidated Financial Statements Of The Company For The Second ....
Regulatory Filings
2023-11-14 English
VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 ,inter alia, to consider and approve the Un-Audited Financial Results ....
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) informing about the date of an upcoming Board Meeting scheduled for November 14, 2023. It references Regulation 29(1)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, which pertains to disclosures about board meetings. The letter states that the Board will consider and approve the un-audited financial results for the quarter and half year ended September 30, 2023. The document also mentions the closure of the trading window for insiders around the meeting date. The document is an announcement of a Board Meeting date and agenda, not the actual financial results or report. It is short (1640 characters) and serves as a notification rather than a report or detailed filing. Therefore, it fits the category of Board/Management Information (MANG), which includes announcements of board meetings and related disclosures.
2023-11-03 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.